336882-79-2

Basic information

• Product Name: 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol
• Synonyms: 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol
• CAS NO: 336882-79-2
• Molecular Weight: 373.495
• Mol File: 336882-79-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol(336882-79-2)
• EPA Substance Registry System: 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol(336882-79-2)

Safety Data

• Hazardous Substances Data: 336882-79-2(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 31575-75-4 2-bromophenyl benzyl ether 
• 328000-16-4 (2-(benzyloxy)phenyl)magnesium bromide 

Downstream Products

• 1274933-95-7 4-(2-hydroxy-phenyl)-piperidin-4-ol hydrochloride 
• 336882-26-9 4-(4-hydroxy-4-(2-(6-hydroxyhexyloxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide 
• 336882-05-4 4-(4-hydroxy-4-(2-(3-acetoxypropoxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide 
• 336882-25-8 4-(4-hydroxy-4-(2-(4-hydroxybutyloxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide 
• 336882-04-3 acetic acid 2-{2-[1-(3-dimethylcarbamoyl-3,3-diphenyl-propyl)-4-hydroxy-piperidin-4-yl]-phenoxy}-ethyl ester 
• 336881-95-9 {2-[1-(3-dimethylcarbamoyl-3,3-diphenyl-propyl)-4-hydroxy-piperidin-4-yl]-phenoxy}-acetic acid ethyl ester 
• 336882-16-7 4-(4-hydroxy-4-(2-(3-hydroxypropoxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide 
• 336882-13-4 N,N-dimethyl-2,2-diphenyl-4-[4-hydroxy-4-[2-(carbamoylmethoxy)phenyl]piperidin-1-yl]butanamide 
• 336882-64-5 2-(2-(1-(4-dimethylamino-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)phenoxy)acetic acid 
• 336882-17-8 4-{4-hydroxy-4-[2-(2-hydroxy-ethoxy)-phenyl]-piperidin-1-yl}-N,N-dimethyl-2,2-diphenyl-butyramide 
• 336882-14-5 N,N-dimethyl-2,2-diphenyl-4-[4-hydroxy-4-[2-(2-methoxyethoxy)phenyl]piperidin-1-yl]butanamide 
• 336881-91-5 4-[4-(2-hydroxyphenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenyl-N,N-dimethylbutanamide 
• 336882-80-5 4-hydroxy-4-(2-hydroxyphenyl)piperidine 

Relevant articles and documents

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

New μ-opioid receptor agonists with phenoxyacetic acid moiety

New μ-opioid receptor (MOR) agonists containing 4-hydroxypiperidine, piperidine and piperazine moieties were synthesized and evaluated to find a peripheral opioid analgesic. Among the synthesized compounds, [2-[1-[3-(N,N-dimethylcarbamoyl)-3,3-diphenylpropyl]-4-hydroxypiperidin-4-yl] phenoxy]acetic acid (8: SS620) having phenoxyacetic acid and 4-hydroxypiperidine moieties showed the highest agonist potency on the MOR in an isolated guinea-pig ileum preparation, and it also had selectivity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells compared with the same types of δ- and κ-opioid receptors (DOR and KOR). In addition, compound 8 showed a 10 times more potent MOR agonist activity than loperamide. Furthermore, compound 8 showed a peripheral analgesic activity in vivo screening on rat.